Host Matt Pillar said venture investor Bruce Booth's year-in-review identified roughly 110 companies targeting CD19.
“he identified more than I think 110 companies targeting CD19.”
Person
3 episodes · 4 quoted claims
Host Matt Pillar said venture investor Bruce Booth's year-in-review identified roughly 110 companies targeting CD19.
“he identified more than I think 110 companies targeting CD19.”
The Business of Biotech podcast, produced in partnership with Cytiva, was marking its one-year anniversary at the time of this episode.
“we will be celebrating our one-year anniversary of the Business of Biotech podcast, which coincides with the one-year anniversary of our partner and its production, Cytiva.”
Matt Pillar says he recently interviewed Dietrich Stefan, CEO of New Base Therapeutics, on the podcast about fail-fast, fail-cheap thinking.
“I recently had a conversation on this podcast with Dietrich Stefan, who's the CEO at New Base Therapeutics.”
Matt Pillar says he ran track in high school and college and was a 400-meter intermediate hurdler.
“I was a runner in high school and college and I had a track coach in college.”